Creative use of novel glucose-lowering drugs for type 2 diabetes: where will we head in the next 50 years?
Open Access
- 20 March 2015
- journal article
- Published by Springer Science and Business Media LLC in Diabetologia
- Vol. 58 (8), 1740-1744
- https://doi.org/10.1007/s00125-015-3557-0
Abstract
Research conducted over the last 50 years has produced discoveries on the importance of glucose control for reducing the risk of diabetic complications, the pathophysiology of type 2 diabetes, the development and validation of mechanistic glucose-lowering targets, and the preclinical and clinical development of individual drugs. This science established the different drug classes that are clinically used today in association with lifestyle changes for lowering glucose in type 2 diabetes. For the next 50 years, we can anticipate that science will explore (1) the use of current drugs and, as they become available, newly developed drugs in early (initial) oral combinations followed by intensification with injectable combinations when glycaemia deteriorates, (2) the validation of novel mechanistic biochemical and physiological targets, including indirect effects of future antiobesity drugs, and (3) the development of true disease-modifying strategies based on knowledge of islet cell biology and replacement. This is one of a series of commentaries under the banner ‘50 years forward’, giving personal opinions on future perspectives in diabetes, to celebrate the 50th anniversary of Diabetologia (1965–2015).This publication has 13 references indexed in Scilit:
- β-Cell Failure in Type 2 Diabetes: Postulated Mechanisms and Prospects for Prevention and TreatmentJournal of Clinical Endocrinology & Metabolism, 2014
- Insulin plus incretin: A glucose-lowering strategy for type 2-diabetesWorld Journal of Diabetes, 2014
- Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and futureThe Lancet, 2013
- SGLT-2 inhibitors and their potential in the treatment of diabetesDiabetes, Metabolic Syndrome and Obesity, 2013
- Avoiding hypoglycemia: a key to success for glucose-lowering therapy in type 2 diabetesVascular Health and Risk Management, 2013
- The cardiovascular safety of incretin-based therapies: a review of the evidenceCardiovascular Diabetology, 2013
- Glycaemic efficacy of glucagon‐like peptide‐1 receptor agonists and dipeptidyl peptidase‐4 inhibitors as add‐on therapy to metformin in subjects with type 2 diabetes—a review and meta analysisDiabetes, Obesity and Metabolism, 2012
- Management of type 2 diabetes: new and future developments in treatmentThe Lancet, 2011
- 10-Year Follow-up of Intensive Glucose Control in Type 2 DiabetesThe New England Journal of Medicine, 2008
- Novel combination treatment of type 2 diabetes DPP-4 inhibition + metforminVascular Health and Risk Management, 2008